T D Szucs - JoVE Visualize

Showing results (41-50 of 68) with videos related to

Pageof 7

Sort By:

Fortschritte Der Medizin|December 29, 1998

[Costs of intensive insulin therapy in type 1 diabetes mellitus. Experiences from the DCCT study]T D Szucs, A M Smala, T Fischer

European Heart Journal|November 20, 1998

Can Europe afford not to implement evidence-based medicine in heart failure?T D Szucs, A Belisari, L G Mantovani

Praxis|September 12, 2001

[Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study]R Haldemann, T F Lüscher, T D Szucs

Biologicals : Journal of the International Association of Biological Standardization|June 1, 1997

Is preventive medical care worth the cost?T D Szucs, A Belisari, L G Mantovani

Surgical Endoscopy|June 3, 2005

Comparison of resource utilization and long-term quality-of-life outcomes between laparoscopic and conventional colorectal surgeryE Sokolovic, P Buchmann, F Schlomowitsch, et al.

Infection|January 22, 2004

Prospective survey of antibiotic utilization in pediatric hospitalized patients to identify targets for improvement of prescriptionM Potocki, J Goette, T D Szucs, et al.

Medizinische Klinik (Munich, Germany : 1983)|February 24, 2001

[Cost effectiveness of bisoprolol in treatment of heart failure in Germany. An analysis based on the CIBIS-II study]T D Szucs, M Schwenkglenks, B Paschen, et al.

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 14, 1999

Resource implications of febrile neutropenia in cancer patients. An international collaborative studyS Harbarth, I Beeler, M Viot, et al.

Schweizerische Medizinische Wochenschrift|July 22, 1997

[Cost effectiveness of ACE inhibition in therapy of chronic heart failure in Switzerland: evaluation based on the SOLVD study]T D Szucs, M Goedde, K Berger, et al.

Zeitschrift Fur Kardiologie|March 27, 2003

[Costs and cost-effectiveness of Eptifibatide in the treatment of coronary ischemic syndromes. An analysis based on the PURSUIT study]T D Szucs, M Schwenkglenks, K Berger, et al.

Pageof 7

Showing results (41-50 of 68) with videos related to

Sort By:

Pageof 7

Fortschritte Der Medizin|December 29, 1998

[Costs of intensive insulin therapy in type 1 diabetes mellitus. Experiences from the DCCT study]T D Szucs, A M Smala, T Fischer

European Heart Journal|November 20, 1998

Can Europe afford not to implement evidence-based medicine in heart failure?T D Szucs, A Belisari, L G Mantovani

Praxis|September 12, 2001

[Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study]R Haldemann, T F Lüscher, T D Szucs

Biologicals : Journal of the International Association of Biological Standardization|June 1, 1997

Is preventive medical care worth the cost?T D Szucs, A Belisari, L G Mantovani

Surgical Endoscopy|June 3, 2005

Comparison of resource utilization and long-term quality-of-life outcomes between laparoscopic and conventional colorectal surgeryE Sokolovic, P Buchmann, F Schlomowitsch, et al.

Infection|January 22, 2004

Prospective survey of antibiotic utilization in pediatric hospitalized patients to identify targets for improvement of prescriptionM Potocki, J Goette, T D Szucs, et al.

Medizinische Klinik (Munich, Germany : 1983)|February 24, 2001

[Cost effectiveness of bisoprolol in treatment of heart failure in Germany. An analysis based on the CIBIS-II study]T D Szucs, M Schwenkglenks, B Paschen, et al.

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 14, 1999

Resource implications of febrile neutropenia in cancer patients. An international collaborative studyS Harbarth, I Beeler, M Viot, et al.

Schweizerische Medizinische Wochenschrift|July 22, 1997

[Cost effectiveness of ACE inhibition in therapy of chronic heart failure in Switzerland: evaluation based on the SOLVD study]T D Szucs, M Goedde, K Berger, et al.

Zeitschrift Fur Kardiologie|March 27, 2003

[Costs and cost-effectiveness of Eptifibatide in the treatment of coronary ischemic syndromes. An analysis based on the PURSUIT study]T D Szucs, M Schwenkglenks, K Berger, et al.

Pageof 7